EGFR and non-small cell lung carcinoma: The subsequent FLAURA and ADURA trials, respectively, led to the FDA approval of osimertinib in the first-line treatment of metastatic NSCLC and as adjuvant therapy for patients with Stage IB–IIIA EGFR exon 19 deletions or exon 21 L858R mutations.